Review





Similar Products

99
Miltenyi Biotec live cd8 t cells
(A) Timeline for tumor injection and drug treatments. Tumor cells were injected on d0. (B) Tumor growth in individual mice treated with DNMTi (RG108) alone, ICI (anti-CTLA4) alone, or dual therapy (ICI+DNMTi). (C) Overall survival of mice receiving ICI (anti-CTLA4), DNMT1i (RG108 or GSK32), or ICI+DNMT1i (RG108 or GSK32) (log-rank Mantel Cox test). (D) UMAP reduction of identified clusters from 4 treatment groups (DNMTi alone (RG108), ICI (anti-CTLA4) alone, dual therapy, and control) with 3 mice per condition and 2 tissues (tdLN and tumor) from each mouse. (E) UMAP reduction of total CD8+ T cells from tdLN from all 4 treatment groups. (F) Dot plot showing expression of key markers defining each CD8 cluster. (G) UMAP reduction of total CD8+ T cells from tdLN from all 4 treatment groups using Monocle3 for trajectory analysis and (H) trajectory analysis colored by pseudotime. (I) Pseudobulk quantification of the proportion of CD8⁺ T cells in the naïve-like cluster (left) and T PEX cluster (right) (n=3).
Live Cd8 T Cells, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/live+cell/Dead+Cell+Removal+Kit/bio_rxiv__64898__2026__07__03__736412-340-3-14
Average 99 stars, based on 1 article reviews
live cd8 t cells - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

94
MedChemExpress dead staining solution
(A) Timeline for tumor injection and drug treatments. Tumor cells were injected on d0. (B) Tumor growth in individual mice treated with DNMTi (RG108) alone, ICI (anti-CTLA4) alone, or dual therapy (ICI+DNMTi). (C) Overall survival of mice receiving ICI (anti-CTLA4), DNMT1i (RG108 or GSK32), or ICI+DNMT1i (RG108 or GSK32) (log-rank Mantel Cox test). (D) UMAP reduction of identified clusters from 4 treatment groups (DNMTi alone (RG108), ICI (anti-CTLA4) alone, dual therapy, and control) with 3 mice per condition and 2 tissues (tdLN and tumor) from each mouse. (E) UMAP reduction of total CD8+ T cells from tdLN from all 4 treatment groups. (F) Dot plot showing expression of key markers defining each CD8 cluster. (G) UMAP reduction of total CD8+ T cells from tdLN from all 4 treatment groups using Monocle3 for trajectory analysis and (H) trajectory analysis colored by pseudotime. (I) Pseudobulk quantification of the proportion of CD8⁺ T cells in the naïve-like cluster (left) and T PEX cluster (right) (n=3).
Dead Staining Solution, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/live+cell/Viability%2FCytotoxicity+Assay+Kit+for+Live+%26+Dead+Cells/bio_rxiv__64898__2026__07__06__736670-150-1-9
Average 94 stars, based on 1 article reviews
dead staining solution - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

99
Miltenyi Biotec dead cell removal kit
(A) Timeline for tumor injection and drug treatments. Tumor cells were injected on d0. (B) Tumor growth in individual mice treated with DNMTi (RG108) alone, ICI (anti-CTLA4) alone, or dual therapy (ICI+DNMTi). (C) Overall survival of mice receiving ICI (anti-CTLA4), DNMT1i (RG108 or GSK32), or ICI+DNMT1i (RG108 or GSK32) (log-rank Mantel Cox test). (D) UMAP reduction of identified clusters from 4 treatment groups (DNMTi alone (RG108), ICI (anti-CTLA4) alone, dual therapy, and control) with 3 mice per condition and 2 tissues (tdLN and tumor) from each mouse. (E) UMAP reduction of total CD8+ T cells from tdLN from all 4 treatment groups. (F) Dot plot showing expression of key markers defining each CD8 cluster. (G) UMAP reduction of total CD8+ T cells from tdLN from all 4 treatment groups using Monocle3 for trajectory analysis and (H) trajectory analysis colored by pseudotime. (I) Pseudobulk quantification of the proportion of CD8⁺ T cells in the naïve-like cluster (left) and T PEX cluster (right) (n=3).
Dead Cell Removal Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/live+cell/Dead+Cell+Removal+Kit/custom%40130-090-101%4042466067
Average 99 stars, based on 1 article reviews
dead cell removal kit - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

99
Sartorius AG live cell analysis system
(A) Timeline for tumor injection and drug treatments. Tumor cells were injected on d0. (B) Tumor growth in individual mice treated with DNMTi (RG108) alone, ICI (anti-CTLA4) alone, or dual therapy (ICI+DNMTi). (C) Overall survival of mice receiving ICI (anti-CTLA4), DNMT1i (RG108 or GSK32), or ICI+DNMT1i (RG108 or GSK32) (log-rank Mantel Cox test). (D) UMAP reduction of identified clusters from 4 treatment groups (DNMTi alone (RG108), ICI (anti-CTLA4) alone, dual therapy, and control) with 3 mice per condition and 2 tissues (tdLN and tumor) from each mouse. (E) UMAP reduction of total CD8+ T cells from tdLN from all 4 treatment groups. (F) Dot plot showing expression of key markers defining each CD8 cluster. (G) UMAP reduction of total CD8+ T cells from tdLN from all 4 treatment groups using Monocle3 for trajectory analysis and (H) trajectory analysis colored by pseudotime. (I) Pseudobulk quantification of the proportion of CD8⁺ T cells in the naïve-like cluster (left) and T PEX cluster (right) (n=3).
Live Cell Analysis System, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/live+cell/Live+Cell+Analysis+Instruments/pmc13011060-465-15-18
Average 99 stars, based on 1 article reviews
live cell analysis system - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

97
Guangzhou JET Bio-Filtration e-click edu cell proliferation imaging assay kit
(A) Timeline for tumor injection and drug treatments. Tumor cells were injected on d0. (B) Tumor growth in individual mice treated with DNMTi (RG108) alone, ICI (anti-CTLA4) alone, or dual therapy (ICI+DNMTi). (C) Overall survival of mice receiving ICI (anti-CTLA4), DNMT1i (RG108 or GSK32), or ICI+DNMT1i (RG108 or GSK32) (log-rank Mantel Cox test). (D) UMAP reduction of identified clusters from 4 treatment groups (DNMTi alone (RG108), ICI (anti-CTLA4) alone, dual therapy, and control) with 3 mice per condition and 2 tissues (tdLN and tumor) from each mouse. (E) UMAP reduction of total CD8+ T cells from tdLN from all 4 treatment groups. (F) Dot plot showing expression of key markers defining each CD8 cluster. (G) UMAP reduction of total CD8+ T cells from tdLN from all 4 treatment groups using Monocle3 for trajectory analysis and (H) trajectory analysis colored by pseudotime. (I) Pseudobulk quantification of the proportion of CD8⁺ T cells in the naïve-like cluster (left) and T PEX cluster (right) (n=3).
E Click Edu Cell Proliferation Imaging Assay Kit, supplied by Guangzhou JET Bio-Filtration, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/live+cell/E-Click+EdU+Cell+Proliferation+Imaging+Assay+Kit/custom%40e-ck-a376%4042542056
Average 97 stars, based on 1 article reviews
e-click edu cell proliferation imaging assay kit - by Bioz Stars, 2026-08
97/100 stars
  Buy from Supplier

99
Sartorius AG incucyte live cell analysis system
MYCL reduces proliferation while promoting migration and cytoskeletal remodeling and decreasing cell adhesion in prostate cancer cells (A) Proliferation assay. Real-time <t>Incucyte</t> analysis showing cell proliferation of C4-2B control (Ctrl) and C4-2B-MYCL cells measured as confluence (%) over time. Quantification using area under the curve (AUC) demonstrates reduced proliferative capacity following MYCL overexpression. (B) Proliferation assay. Real-time Incucyte analysis showing cell proliferation of PC3 control (Ctrl) and PC3-MYCL cells measured as confluence (%) over time. Quantification using area under the curve (AUC) demonstrates reduced proliferative capacity following MYCL overexpression. (C) Left: Cell cycle analysis of C4-2B and PC3 cells following MYCL overexpression. In PC3 cells, MYCL reduces the G1 population and increases S-phase, indicating altered cell cycle progression, whereas changes in C4-2B cells are minimal. Right: Apoptosis analysis by Annexin V/7-AAD staining. MYCL overexpression in PC3 cells increases the early apoptotic population, with little or no significant change in C4-2B cells. (D) Cell adhesion assay. Cell adhesion was assessed by crystal violet staining and quantified by measuring absorbance at 595 nm at 18, 24, 48, and 72 h following seeding. MYCL-overexpressing C4-2B cells exhibited significantly decreased adhesion compared with control cells. Representative phase-contrast images acquired 48 h after seeding show reduced cell attachment and increased cell clustering in MYCL-expressing cells. (E) Molecular validation. RT-qPCR analysis of adhesion-related genes (ITGB1, ITGAV) in control (Ctrl) and MYCL-overexpressing C4-2B, LNCaP and PC3 cells. (F) Migration assay. Wound-healing analysis measuring relative wound density (%) over time demonstrates moderately enhanced migratory capacity in PC3-MYCL cells. AUC quantification confirms increased migration upon MYCL expression. (G) Cytoskeletal transcriptional programs. Heatmap showing differential expression of genes meeting thresholds of |log₂FC| ≥ 0.5 and adjusted p-value (FDR) < 0.05. Differentially regulated genes are associated with Ephrin-EPH signaling, Rho-Rac signaling, cytoskeletal organization, cell-cell junctions, extracellular matrix (ECM) interactions, and epithelial-mesenchymal transition (EMT) regulators, indicating MYCL-driven cytoskeletal remodeling signatures.
Incucyte Live Cell Analysis System, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/live+cell/Live+Cell+Analysis+Instruments/pmc13098336-320-14-18
Average 99 stars, based on 1 article reviews
incucyte live cell analysis system - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

99
Sartorius AG incucyte system
MYCL reduces proliferation while promoting migration and cytoskeletal remodeling and decreasing cell adhesion in prostate cancer cells (A) Proliferation assay. Real-time <t>Incucyte</t> analysis showing cell proliferation of C4-2B control (Ctrl) and C4-2B-MYCL cells measured as confluence (%) over time. Quantification using area under the curve (AUC) demonstrates reduced proliferative capacity following MYCL overexpression. (B) Proliferation assay. Real-time Incucyte analysis showing cell proliferation of PC3 control (Ctrl) and PC3-MYCL cells measured as confluence (%) over time. Quantification using area under the curve (AUC) demonstrates reduced proliferative capacity following MYCL overexpression. (C) Left: Cell cycle analysis of C4-2B and PC3 cells following MYCL overexpression. In PC3 cells, MYCL reduces the G1 population and increases S-phase, indicating altered cell cycle progression, whereas changes in C4-2B cells are minimal. Right: Apoptosis analysis by Annexin V/7-AAD staining. MYCL overexpression in PC3 cells increases the early apoptotic population, with little or no significant change in C4-2B cells. (D) Cell adhesion assay. Cell adhesion was assessed by crystal violet staining and quantified by measuring absorbance at 595 nm at 18, 24, 48, and 72 h following seeding. MYCL-overexpressing C4-2B cells exhibited significantly decreased adhesion compared with control cells. Representative phase-contrast images acquired 48 h after seeding show reduced cell attachment and increased cell clustering in MYCL-expressing cells. (E) Molecular validation. RT-qPCR analysis of adhesion-related genes (ITGB1, ITGAV) in control (Ctrl) and MYCL-overexpressing C4-2B, LNCaP and PC3 cells. (F) Migration assay. Wound-healing analysis measuring relative wound density (%) over time demonstrates moderately enhanced migratory capacity in PC3-MYCL cells. AUC quantification confirms increased migration upon MYCL expression. (G) Cytoskeletal transcriptional programs. Heatmap showing differential expression of genes meeting thresholds of |log₂FC| ≥ 0.5 and adjusted p-value (FDR) < 0.05. Differentially regulated genes are associated with Ephrin-EPH signaling, Rho-Rac signaling, cytoskeletal organization, cell-cell junctions, extracellular matrix (ECM) interactions, and epithelial-mesenchymal transition (EMT) regulators, indicating MYCL-driven cytoskeletal remodeling signatures.
Incucyte System, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/live+cell/Live+Cell+Analysis+Instruments/pmc13098336-322-11-16
Average 99 stars, based on 1 article reviews
incucyte system - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

99
Sartorius AG incucyte organoid analysis software module
Oxygen consumption rate (OCR) in the presence or absence of spheroids (A) <t>Incucyte</t> image of spheroid in the center of the microplate well at the end of the assay and (B) the corresponding OCR kinetic graph showing a response after drug injections as expected. (C) Image of a microplate well with no spheroid detected at the end of the assay and (D) corresponding OCR kinetic graph showing no response after drug injections.
Incucyte Organoid Analysis Software Module, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/live+cell/Live+Cell+Analysis+Instruments/pmc13127629-50-0-6
Average 99 stars, based on 1 article reviews
incucyte organoid analysis software module - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

86
Keygen Biotech live dead cell staining kit
Oxygen consumption rate (OCR) in the presence or absence of spheroids (A) <t>Incucyte</t> image of spheroid in the center of the microplate well at the end of the assay and (B) the corresponding OCR kinetic graph showing a response after drug injections as expected. (C) Image of a microplate well with no spheroid detected at the end of the assay and (D) corresponding OCR kinetic graph showing no response after drug injections.
Live Dead Cell Staining Kit, supplied by Keygen Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/live+cell/cell+dead+kit+live+staining/pm42315363-267-8-15
Average 86 stars, based on 1 article reviews
live dead cell staining kit - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

99
Sartorius AG incucyte s3 live cell analysis system
Oxygen consumption rate (OCR) in the presence or absence of spheroids (A) <t>Incucyte</t> image of spheroid in the center of the microplate well at the end of the assay and (B) the corresponding OCR kinetic graph showing a response after drug injections as expected. (C) Image of a microplate well with no spheroid detected at the end of the assay and (D) corresponding OCR kinetic graph showing no response after drug injections.
Incucyte S3 Live Cell Analysis System, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/live+cell/Live+Cell+Analysis+Instruments/pmc13127629-39-0-6
Average 99 stars, based on 1 article reviews
incucyte s3 live cell analysis system - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

Image Search Results


(A) Timeline for tumor injection and drug treatments. Tumor cells were injected on d0. (B) Tumor growth in individual mice treated with DNMTi (RG108) alone, ICI (anti-CTLA4) alone, or dual therapy (ICI+DNMTi). (C) Overall survival of mice receiving ICI (anti-CTLA4), DNMT1i (RG108 or GSK32), or ICI+DNMT1i (RG108 or GSK32) (log-rank Mantel Cox test). (D) UMAP reduction of identified clusters from 4 treatment groups (DNMTi alone (RG108), ICI (anti-CTLA4) alone, dual therapy, and control) with 3 mice per condition and 2 tissues (tdLN and tumor) from each mouse. (E) UMAP reduction of total CD8+ T cells from tdLN from all 4 treatment groups. (F) Dot plot showing expression of key markers defining each CD8 cluster. (G) UMAP reduction of total CD8+ T cells from tdLN from all 4 treatment groups using Monocle3 for trajectory analysis and (H) trajectory analysis colored by pseudotime. (I) Pseudobulk quantification of the proportion of CD8⁺ T cells in the naïve-like cluster (left) and T PEX cluster (right) (n=3).

Journal: bioRxiv

Article Title: Targeting DNMT1 augments anti-tumor CD8⁺ T cell function

doi: 10.64898/2026.07.03.736412

Figure Lengend Snippet: (A) Timeline for tumor injection and drug treatments. Tumor cells were injected on d0. (B) Tumor growth in individual mice treated with DNMTi (RG108) alone, ICI (anti-CTLA4) alone, or dual therapy (ICI+DNMTi). (C) Overall survival of mice receiving ICI (anti-CTLA4), DNMT1i (RG108 or GSK32), or ICI+DNMT1i (RG108 or GSK32) (log-rank Mantel Cox test). (D) UMAP reduction of identified clusters from 4 treatment groups (DNMTi alone (RG108), ICI (anti-CTLA4) alone, dual therapy, and control) with 3 mice per condition and 2 tissues (tdLN and tumor) from each mouse. (E) UMAP reduction of total CD8+ T cells from tdLN from all 4 treatment groups. (F) Dot plot showing expression of key markers defining each CD8 cluster. (G) UMAP reduction of total CD8+ T cells from tdLN from all 4 treatment groups using Monocle3 for trajectory analysis and (H) trajectory analysis colored by pseudotime. (I) Pseudobulk quantification of the proportion of CD8⁺ T cells in the naïve-like cluster (left) and T PEX cluster (right) (n=3).

Article Snippet: On day 7, live CD8+ T cells were enriched using a dead-cell removal kit (Miltenyi) and added to tumor cells at a 1:10 T-cell:tumor ratio.

Techniques: Injection, Control, Expressing

(A) Schematic of in vitro primary P14 CD8+ T cell culture model. (B) Schematic describing abbreviated nomenclature for in vitro cell states (T M , T EX , T EX+D , T M* , T EX* , T EX+D* ). (C) P14 CD8⁺ T cells were isolated on d7 of culture and restimulated with gp33 peptide for flow cytometry analysis of IFNγ and TNFα production (left) or co-cultured with gp33-expressing mouse melanoma line YUMM-G1-gp33 to assess tumor cell killing (right) by flow cytometry (n=3). (D) Chronic stimulation promotes proliferation of CD8+ T cells as shown by CellTrace Violet dilution (left) and quantified as proportion of cells in each generation (right) (n=3). (E-F) Violin plots showing differentially expressed genes between T EX+D and T EX (E) and between T EX+D* and T EX* (F) with RG108 (left) or with GSK32 (right). An adjusted p-value cutoff of 0.05 and log2FC cutoff of 0.5 were used. (G) UMAP depicting clusters obtained using PhenoGraph for concatenated samples (top left) and density plots for TEX* (top right), TEX+D* (GSK-32) (bottom left), and TEX+D* (RG108). (H) Proportion of live, CD45+ cells in MC4 (left) and MC14 (right) across samples. (I) Heatmap representing the relative expression of markers across clusters. (J) Schematic showing consensus nonnegative matrix factorization (cNMF) matrices. (K) Gene by program matrix from cNMF showing loadings for genes in the top 150 ranked gene list for each module. (L) Comparison of T EX vs T EX+D usage of Program S (left) and Program E1(right). (M) Comparison of T EX vs T EX+D usage of Program E2 (left) and Program E3 (right). (N) Comparison of T EX* vs T EX+D* usage of Program E1 (left) and Program E3 (right).

Journal: bioRxiv

Article Title: Targeting DNMT1 augments anti-tumor CD8⁺ T cell function

doi: 10.64898/2026.07.03.736412

Figure Lengend Snippet: (A) Schematic of in vitro primary P14 CD8+ T cell culture model. (B) Schematic describing abbreviated nomenclature for in vitro cell states (T M , T EX , T EX+D , T M* , T EX* , T EX+D* ). (C) P14 CD8⁺ T cells were isolated on d7 of culture and restimulated with gp33 peptide for flow cytometry analysis of IFNγ and TNFα production (left) or co-cultured with gp33-expressing mouse melanoma line YUMM-G1-gp33 to assess tumor cell killing (right) by flow cytometry (n=3). (D) Chronic stimulation promotes proliferation of CD8+ T cells as shown by CellTrace Violet dilution (left) and quantified as proportion of cells in each generation (right) (n=3). (E-F) Violin plots showing differentially expressed genes between T EX+D and T EX (E) and between T EX+D* and T EX* (F) with RG108 (left) or with GSK32 (right). An adjusted p-value cutoff of 0.05 and log2FC cutoff of 0.5 were used. (G) UMAP depicting clusters obtained using PhenoGraph for concatenated samples (top left) and density plots for TEX* (top right), TEX+D* (GSK-32) (bottom left), and TEX+D* (RG108). (H) Proportion of live, CD45+ cells in MC4 (left) and MC14 (right) across samples. (I) Heatmap representing the relative expression of markers across clusters. (J) Schematic showing consensus nonnegative matrix factorization (cNMF) matrices. (K) Gene by program matrix from cNMF showing loadings for genes in the top 150 ranked gene list for each module. (L) Comparison of T EX vs T EX+D usage of Program S (left) and Program E1(right). (M) Comparison of T EX vs T EX+D usage of Program E2 (left) and Program E3 (right). (N) Comparison of T EX* vs T EX+D* usage of Program E1 (left) and Program E3 (right).

Article Snippet: On day 7, live CD8+ T cells were enriched using a dead-cell removal kit (Miltenyi) and added to tumor cells at a 1:10 T-cell:tumor ratio.

Techniques: In Vitro, Cell Culture, Isolation, Flow Cytometry, Expressing, Comparison

MYCL reduces proliferation while promoting migration and cytoskeletal remodeling and decreasing cell adhesion in prostate cancer cells (A) Proliferation assay. Real-time Incucyte analysis showing cell proliferation of C4-2B control (Ctrl) and C4-2B-MYCL cells measured as confluence (%) over time. Quantification using area under the curve (AUC) demonstrates reduced proliferative capacity following MYCL overexpression. (B) Proliferation assay. Real-time Incucyte analysis showing cell proliferation of PC3 control (Ctrl) and PC3-MYCL cells measured as confluence (%) over time. Quantification using area under the curve (AUC) demonstrates reduced proliferative capacity following MYCL overexpression. (C) Left: Cell cycle analysis of C4-2B and PC3 cells following MYCL overexpression. In PC3 cells, MYCL reduces the G1 population and increases S-phase, indicating altered cell cycle progression, whereas changes in C4-2B cells are minimal. Right: Apoptosis analysis by Annexin V/7-AAD staining. MYCL overexpression in PC3 cells increases the early apoptotic population, with little or no significant change in C4-2B cells. (D) Cell adhesion assay. Cell adhesion was assessed by crystal violet staining and quantified by measuring absorbance at 595 nm at 18, 24, 48, and 72 h following seeding. MYCL-overexpressing C4-2B cells exhibited significantly decreased adhesion compared with control cells. Representative phase-contrast images acquired 48 h after seeding show reduced cell attachment and increased cell clustering in MYCL-expressing cells. (E) Molecular validation. RT-qPCR analysis of adhesion-related genes (ITGB1, ITGAV) in control (Ctrl) and MYCL-overexpressing C4-2B, LNCaP and PC3 cells. (F) Migration assay. Wound-healing analysis measuring relative wound density (%) over time demonstrates moderately enhanced migratory capacity in PC3-MYCL cells. AUC quantification confirms increased migration upon MYCL expression. (G) Cytoskeletal transcriptional programs. Heatmap showing differential expression of genes meeting thresholds of |log₂FC| ≥ 0.5 and adjusted p-value (FDR) < 0.05. Differentially regulated genes are associated with Ephrin-EPH signaling, Rho-Rac signaling, cytoskeletal organization, cell-cell junctions, extracellular matrix (ECM) interactions, and epithelial-mesenchymal transition (EMT) regulators, indicating MYCL-driven cytoskeletal remodeling signatures.

Journal: Neoplasia (New York, N.Y.)

Article Title: A MYC family switch: L-MYC drives and maintains neuroendocrine lineage programs in prostate cancer

doi: 10.1016/j.neo.2026.101307

Figure Lengend Snippet: MYCL reduces proliferation while promoting migration and cytoskeletal remodeling and decreasing cell adhesion in prostate cancer cells (A) Proliferation assay. Real-time Incucyte analysis showing cell proliferation of C4-2B control (Ctrl) and C4-2B-MYCL cells measured as confluence (%) over time. Quantification using area under the curve (AUC) demonstrates reduced proliferative capacity following MYCL overexpression. (B) Proliferation assay. Real-time Incucyte analysis showing cell proliferation of PC3 control (Ctrl) and PC3-MYCL cells measured as confluence (%) over time. Quantification using area under the curve (AUC) demonstrates reduced proliferative capacity following MYCL overexpression. (C) Left: Cell cycle analysis of C4-2B and PC3 cells following MYCL overexpression. In PC3 cells, MYCL reduces the G1 population and increases S-phase, indicating altered cell cycle progression, whereas changes in C4-2B cells are minimal. Right: Apoptosis analysis by Annexin V/7-AAD staining. MYCL overexpression in PC3 cells increases the early apoptotic population, with little or no significant change in C4-2B cells. (D) Cell adhesion assay. Cell adhesion was assessed by crystal violet staining and quantified by measuring absorbance at 595 nm at 18, 24, 48, and 72 h following seeding. MYCL-overexpressing C4-2B cells exhibited significantly decreased adhesion compared with control cells. Representative phase-contrast images acquired 48 h after seeding show reduced cell attachment and increased cell clustering in MYCL-expressing cells. (E) Molecular validation. RT-qPCR analysis of adhesion-related genes (ITGB1, ITGAV) in control (Ctrl) and MYCL-overexpressing C4-2B, LNCaP and PC3 cells. (F) Migration assay. Wound-healing analysis measuring relative wound density (%) over time demonstrates moderately enhanced migratory capacity in PC3-MYCL cells. AUC quantification confirms increased migration upon MYCL expression. (G) Cytoskeletal transcriptional programs. Heatmap showing differential expression of genes meeting thresholds of |log₂FC| ≥ 0.5 and adjusted p-value (FDR) < 0.05. Differentially regulated genes are associated with Ephrin-EPH signaling, Rho-Rac signaling, cytoskeletal organization, cell-cell junctions, extracellular matrix (ECM) interactions, and epithelial-mesenchymal transition (EMT) regulators, indicating MYCL-driven cytoskeletal remodeling signatures.

Article Snippet: For live-cell proliferation analysis, cells were seeded in 96-well plates and monitored using the IncuCyte® Live-Cell Analysis System (Sartorius).

Techniques: Migration, Proliferation Assay, Control, Over Expression, Cell Cycle Assay, Staining, Cell Adhesion Assay, Cell Attachment Assay, Expressing, Biomarker Discovery, Quantitative RT-PCR, Quantitative Proteomics

MYCL reduces proliferation while promoting migration and cytoskeletal remodeling and decreasing cell adhesion in prostate cancer cells (A) Proliferation assay. Real-time Incucyte analysis showing cell proliferation of C4-2B control (Ctrl) and C4-2B-MYCL cells measured as confluence (%) over time. Quantification using area under the curve (AUC) demonstrates reduced proliferative capacity following MYCL overexpression. (B) Proliferation assay. Real-time Incucyte analysis showing cell proliferation of PC3 control (Ctrl) and PC3-MYCL cells measured as confluence (%) over time. Quantification using area under the curve (AUC) demonstrates reduced proliferative capacity following MYCL overexpression. (C) Left: Cell cycle analysis of C4-2B and PC3 cells following MYCL overexpression. In PC3 cells, MYCL reduces the G1 population and increases S-phase, indicating altered cell cycle progression, whereas changes in C4-2B cells are minimal. Right: Apoptosis analysis by Annexin V/7-AAD staining. MYCL overexpression in PC3 cells increases the early apoptotic population, with little or no significant change in C4-2B cells. (D) Cell adhesion assay. Cell adhesion was assessed by crystal violet staining and quantified by measuring absorbance at 595 nm at 18, 24, 48, and 72 h following seeding. MYCL-overexpressing C4-2B cells exhibited significantly decreased adhesion compared with control cells. Representative phase-contrast images acquired 48 h after seeding show reduced cell attachment and increased cell clustering in MYCL-expressing cells. (E) Molecular validation. RT-qPCR analysis of adhesion-related genes (ITGB1, ITGAV) in control (Ctrl) and MYCL-overexpressing C4-2B, LNCaP and PC3 cells. (F) Migration assay. Wound-healing analysis measuring relative wound density (%) over time demonstrates moderately enhanced migratory capacity in PC3-MYCL cells. AUC quantification confirms increased migration upon MYCL expression. (G) Cytoskeletal transcriptional programs. Heatmap showing differential expression of genes meeting thresholds of |log₂FC| ≥ 0.5 and adjusted p-value (FDR) < 0.05. Differentially regulated genes are associated with Ephrin-EPH signaling, Rho-Rac signaling, cytoskeletal organization, cell-cell junctions, extracellular matrix (ECM) interactions, and epithelial-mesenchymal transition (EMT) regulators, indicating MYCL-driven cytoskeletal remodeling signatures.

Journal: Neoplasia (New York, N.Y.)

Article Title: A MYC family switch: L-MYC drives and maintains neuroendocrine lineage programs in prostate cancer

doi: 10.1016/j.neo.2026.101307

Figure Lengend Snippet: MYCL reduces proliferation while promoting migration and cytoskeletal remodeling and decreasing cell adhesion in prostate cancer cells (A) Proliferation assay. Real-time Incucyte analysis showing cell proliferation of C4-2B control (Ctrl) and C4-2B-MYCL cells measured as confluence (%) over time. Quantification using area under the curve (AUC) demonstrates reduced proliferative capacity following MYCL overexpression. (B) Proliferation assay. Real-time Incucyte analysis showing cell proliferation of PC3 control (Ctrl) and PC3-MYCL cells measured as confluence (%) over time. Quantification using area under the curve (AUC) demonstrates reduced proliferative capacity following MYCL overexpression. (C) Left: Cell cycle analysis of C4-2B and PC3 cells following MYCL overexpression. In PC3 cells, MYCL reduces the G1 population and increases S-phase, indicating altered cell cycle progression, whereas changes in C4-2B cells are minimal. Right: Apoptosis analysis by Annexin V/7-AAD staining. MYCL overexpression in PC3 cells increases the early apoptotic population, with little or no significant change in C4-2B cells. (D) Cell adhesion assay. Cell adhesion was assessed by crystal violet staining and quantified by measuring absorbance at 595 nm at 18, 24, 48, and 72 h following seeding. MYCL-overexpressing C4-2B cells exhibited significantly decreased adhesion compared with control cells. Representative phase-contrast images acquired 48 h after seeding show reduced cell attachment and increased cell clustering in MYCL-expressing cells. (E) Molecular validation. RT-qPCR analysis of adhesion-related genes (ITGB1, ITGAV) in control (Ctrl) and MYCL-overexpressing C4-2B, LNCaP and PC3 cells. (F) Migration assay. Wound-healing analysis measuring relative wound density (%) over time demonstrates moderately enhanced migratory capacity in PC3-MYCL cells. AUC quantification confirms increased migration upon MYCL expression. (G) Cytoskeletal transcriptional programs. Heatmap showing differential expression of genes meeting thresholds of |log₂FC| ≥ 0.5 and adjusted p-value (FDR) < 0.05. Differentially regulated genes are associated with Ephrin-EPH signaling, Rho-Rac signaling, cytoskeletal organization, cell-cell junctions, extracellular matrix (ECM) interactions, and epithelial-mesenchymal transition (EMT) regulators, indicating MYCL-driven cytoskeletal remodeling signatures.

Article Snippet: Cell migration was evaluated using a wound-healing assay performed with the IncuCyte® system following the manufacturer’s (Sartorius) protocol.

Techniques: Migration, Proliferation Assay, Control, Over Expression, Cell Cycle Assay, Staining, Cell Adhesion Assay, Cell Attachment Assay, Expressing, Biomarker Discovery, Quantitative RT-PCR, Quantitative Proteomics

Oxygen consumption rate (OCR) in the presence or absence of spheroids (A) Incucyte image of spheroid in the center of the microplate well at the end of the assay and (B) the corresponding OCR kinetic graph showing a response after drug injections as expected. (C) Image of a microplate well with no spheroid detected at the end of the assay and (D) corresponding OCR kinetic graph showing no response after drug injections.

Journal: STAR Protocols

Article Title: Protocol for Seahorse 3D Mito Stress assay in patient-derived atypical teratoid rhabdoid tumor CHLA-05-ATRT single neurospheres

doi: 10.1016/j.xpro.2026.104515

Figure Lengend Snippet: Oxygen consumption rate (OCR) in the presence or absence of spheroids (A) Incucyte image of spheroid in the center of the microplate well at the end of the assay and (B) the corresponding OCR kinetic graph showing a response after drug injections as expected. (C) Image of a microplate well with no spheroid detected at the end of the assay and (D) corresponding OCR kinetic graph showing no response after drug injections.

Article Snippet: Incucyte Organoid Analysis Software Module , Sartorius , 9600–0034.

Techniques:

Effect of coating timing on spheroid retention in microplate wells (A) Incucyte image of a poly-lysine coated microplate with spheroids transferred on the same day as the assay, taken before the assay. (B) Image of the same plate taken after the assay, showing that the spheroids were displaced and/or destroyed during the assay. (C) Image of a poly-lysine coated microplate with spheroids transferred the day before the assay, taken before the assay and (D) after the assay, showing that the spheroids were intact.

Journal: STAR Protocols

Article Title: Protocol for Seahorse 3D Mito Stress assay in patient-derived atypical teratoid rhabdoid tumor CHLA-05-ATRT single neurospheres

doi: 10.1016/j.xpro.2026.104515

Figure Lengend Snippet: Effect of coating timing on spheroid retention in microplate wells (A) Incucyte image of a poly-lysine coated microplate with spheroids transferred on the same day as the assay, taken before the assay. (B) Image of the same plate taken after the assay, showing that the spheroids were displaced and/or destroyed during the assay. (C) Image of a poly-lysine coated microplate with spheroids transferred the day before the assay, taken before the assay and (D) after the assay, showing that the spheroids were intact.

Article Snippet: Incucyte Organoid Analysis Software Module , Sartorius , 9600–0034.

Techniques:

Oxygen consumption rate (OCR) in the presence or absence of spheroids (A) Incucyte image of spheroid in the center of the microplate well at the end of the assay and (B) the corresponding OCR kinetic graph showing a response after drug injections as expected. (C) Image of a microplate well with no spheroid detected at the end of the assay and (D) corresponding OCR kinetic graph showing no response after drug injections.

Journal: STAR Protocols

Article Title: Protocol for Seahorse 3D Mito Stress assay in patient-derived atypical teratoid rhabdoid tumor CHLA-05-ATRT single neurospheres

doi: 10.1016/j.xpro.2026.104515

Figure Lengend Snippet: Oxygen consumption rate (OCR) in the presence or absence of spheroids (A) Incucyte image of spheroid in the center of the microplate well at the end of the assay and (B) the corresponding OCR kinetic graph showing a response after drug injections as expected. (C) Image of a microplate well with no spheroid detected at the end of the assay and (D) corresponding OCR kinetic graph showing no response after drug injections.

Article Snippet: Incucyte S3 Live-Cell analysis system , Sartorius , 4647.

Techniques:

Effect of coating timing on spheroid retention in microplate wells (A) Incucyte image of a poly-lysine coated microplate with spheroids transferred on the same day as the assay, taken before the assay. (B) Image of the same plate taken after the assay, showing that the spheroids were displaced and/or destroyed during the assay. (C) Image of a poly-lysine coated microplate with spheroids transferred the day before the assay, taken before the assay and (D) after the assay, showing that the spheroids were intact.

Journal: STAR Protocols

Article Title: Protocol for Seahorse 3D Mito Stress assay in patient-derived atypical teratoid rhabdoid tumor CHLA-05-ATRT single neurospheres

doi: 10.1016/j.xpro.2026.104515

Figure Lengend Snippet: Effect of coating timing on spheroid retention in microplate wells (A) Incucyte image of a poly-lysine coated microplate with spheroids transferred on the same day as the assay, taken before the assay. (B) Image of the same plate taken after the assay, showing that the spheroids were displaced and/or destroyed during the assay. (C) Image of a poly-lysine coated microplate with spheroids transferred the day before the assay, taken before the assay and (D) after the assay, showing that the spheroids were intact.

Article Snippet: Incucyte S3 Live-Cell analysis system , Sartorius , 4647.

Techniques: